XTL Biopharmaceuticals Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of June 2026 for XTL Biopharmaceuticals Ltd., a foreign private issuer headquartered in Ramat Gan, Israel. The report details the status of an Extraordinary General Meeting of Shareholders convened on June 22, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice regarding a shareholder meeting and contains no financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary event is the procedural adjournment of a shareholder meeting due to a lack of quorum.
Outlook, Risks, and Management Commentary
Management has announced that the Extraordinary General Meeting originally scheduled for June 22, 2026, was adjourned for one week. The meeting will be reconvened on Monday, June 29, 2026, at 4:00 p.m. Israel time. The location remains the offices of the Company's attorneys, Amit, Pollak, Matalon & Co., in Tel Aviv, Israel. No specific risks, contingencies, or unusual items are disclosed beyond the meeting logistics.
Key Facts for Investor Verification
- The Extraordinary General Meeting was adjourned on June 22, 2026, due to a lack of quorum.
- The meeting is rescheduled for June 29, 2026, at 4:00 p.m. Israel time.
- The reconvened meeting will be held at Amit, Pollak, Matalon & Co. in Tel Aviv.
- This filing contains no financial performance data or updated guidance.